Basket cover image
15 handpicked stocks

Winning Confectionery

This carefully curated collection features the market leaders in candy, chocolate, and sweet treats. Handpicked by our analysts, these companies deliver the small indulgences consumers consistently buy, even during economic downturns.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

HSY

Hershey Company, The

HSY

Current price

$180.77

As a leading American chocolate manufacturer, it owns iconic brands like Hershey's, Reese's, and Kit Kat.

MDLZ

Mondelez International, Inc.

MDLZ

Current price

$62.66

This global snacking powerhouse owns several major confectionery brands, including Cadbury, Milka, and Toblerone.

RMCF

Rocky Mountain Chocolate Factory Inc (Delaware)

RMCF

Current price

$1.21

It operates as a dedicated franchisor and producer of gourmet chocolates, caramels, and other confectionery.

About This Group of Stocks

1

Our Expert Thinking

We've identified the confectionery giants that dominate the world's sweet cravings. These companies offer defensive growth potential through their established brands and consistent consumer demand for affordable luxuries, regardless of economic conditions.

2

What You Need to Know

These stocks combine stability with growth opportunities. Many are consumer staples with substantial market share, global distribution networks, and consistent innovation pipelines. Several also offer dividend income, making them potentially attractive for balanced portfolios.

3

Why These Stocks

Our analysts selected these companies for their brand power, proven track records, and ability to adapt to changing consumer preferences. From chocolate giants to bakery leaders, each has demonstrated expertise in creating products consumers love while expanding into new markets.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+23.77%

Group Performance Snapshot

23.77%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 23.77% over the next year.

9 of 15

Stocks Rated Buy by Analysts

9 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🍫

Sweet Treats, Sweeter Returns

These companies create the guilty pleasures consumers consistently purchase, offering potential stability when other sectors falter.

🌍

Global Growth Appetite

Emerging markets present massive growth opportunities as rising incomes fuel demand for branded sweet treats across Asia, Africa, and Latin America.

💰

Recession-Resistant Rewards

History shows people still buy affordable luxuries during economic downturns, making confectionery stocks potentially resilient when other investments struggle.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.